Biovie (BIVIW) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $0.29, +26.03% vs the prior close of $0.23.
- Volume 1.47K shares, 0.0x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BIVIW jumps 26.0% to $0.29. Closed at $0.29, +26.03% vs the prior close of $0.23. Day range $0.25–$0.29, opened at $0.25.
BIVIW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — BIVIW jumps 26.0% to $0.29
- Closed at $0.29, +26.03% vs the prior close of $0.23. Day range $0.25–$0.29, opened at $0.25.
- Volume was 1.47K shares, 0.0x its 50-day average of 191.67K — lighter than usual.
- 52-week range $0.23–$0.29; today's close sits at 100% of that range, at a new 52-week high.
BIVIW bull case vs bear case (from the data)
- Insiders made 16 open-market purchases in the last 12 months.
- Latest fiscal-year net income: loss of $22.07M.
- High volatility: average daily move of 26.0% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
BIVIW latest news & SEC filings
Every SEC filing by or about BIVIW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Sep 14, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 3, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Palumbo Joseph M bought 4,843 shares at $2.16 (≈$10.46K) on Aug 28, 2026
- Palumbo Joseph M bought 4,843 shares at $2.16 (≈$10.46K) on Aug 28, 2026
- Palumbo Joseph M bought 4,843 shares at $2.16 (≈$10.46K) on Aug 28, 2026
- Palumbo Joseph M bought 4,843 shares at $2.16 (≈$10.46K) on Aug 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Chappell Amy Suzon bought 727 shares at $2.16 (≈$1.57K) on Aug 28, 2026
- Chappell Amy Suzon bought 727 shares at $2.16 (≈$1.57K) on Aug 28, 2026
- Chappell Amy Suzon bought 727 shares at $2.16 (≈$1.57K) on Aug 28, 2026
- Chappell Amy Suzon bought 727 shares at $2.16 (≈$1.57K) on Aug 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kim Joanne Wendy bought 2,500 shares at $2.18 (≈$5.45K) on Aug 28, 2026
- Kim Joanne Wendy bought 2,500 shares at $2.18 (≈$5.45K) on Aug 28, 2026
- Kim Joanne Wendy bought 2,500 shares at $2.18 (≈$5.45K) on Aug 28, 2026
- Kim Joanne Wendy bought 2,500 shares at $2.18 (≈$5.45K) on Aug 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Do Cuong V bought 15,210 shares at $2.08 (≈$31.64K) on Aug 27, 2026
- Do Cuong V bought 15,210 shares at $2.08 (≈$31.64K) on Aug 27, 2026
- Do Cuong V bought 15,210 shares at $2.08 (≈$31.64K) on Aug 27, 2026
- Do Cuong V bought 15,210 shares at $2.08 (≈$31.64K) on Aug 27, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form S-1/A — S-1/A filing
S-1/A filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 13, 2026 · Form 10-K — Annual report
Annual report (audited full-year financial statements and business review)
Fiscal year ended Jun 30, 2026:
- Net income: -$22.07M (prior year -$17.54M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$3.05 (prior year -$12.12) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form FWP — Free writing prospectus (offering marketing material)
Free writing prospectus (offering marketing material)
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade BIVIW
- How much it moves: over the last 20 sessions the average daily move was 26.03% (largest 26.0%). That is a volatile stock.
- Liquidity: about 96.57K shares (≈$28.01K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.29 vs a range of $0.23–$0.29 (100% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 16 open-market buys, 0 sales; latest: Joanne Wendy Kim bought 2,500 shares on Aug 28, 2026.
- Latest filings: 8-K Sep 14, 2026; 10-K Aug 13, 2026; 8-K Aug 6, 2026.
- Share count: 7.54M shares outstanding (Aug 10, 2026), +0.1% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BIVIW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 0.25 | 0.29 | 0.25 | 0.29 | 1.47K |
| Oct 16, 2026 | 0.25 | 0.26 | 0.23 | 0.23 | 191.67K |
About Biovie
Biovie (BIVIW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CARSON CITY, NV. State of incorporation: NV. Fiscal year ends June 30. SEC CIK 1580149.
BIVIW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Amy Suzon Chappell | Director | Aug 28, 2026 |
| Cuong V Do | President & CEO | Aug 28, 2026 |
| Kameel D. Farag | Director | Jan 9, 2026 |
| James Paul Lang | Director | Jan 9, 2026 |
| Sigmund Rogich | Director | Jan 9, 2026 |
| Michael Edward Sherman | Director | Jan 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Cuong V Do | President & CEO | Aug 28, 2026 |
| Joanne Wendy Kim | Chief Financial Officer | Aug 28, 2026 |
| Joseph M Palumbo | Chief Medical Officer | Aug 28, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | Joanne Wendy Kim | Buy | 2,500 | $2.18 |
| Aug 28, 2026 | Joanne Wendy Kim | Buy | 2,500 | $2.18 |
| Aug 28, 2026 | Joanne Wendy Kim | Buy | 2,500 | $2.18 |
| Aug 28, 2026 | Joanne Wendy Kim | Buy | 2,500 | $2.18 |
| Aug 28, 2026 | Joseph M Palumbo | Buy | 4,843 | $2.16 |
| Aug 28, 2026 | Joseph M Palumbo | Buy | 4,843 | $2.16 |
| Aug 28, 2026 | Joseph M Palumbo | Buy | 4,843 | $2.16 |
| Aug 28, 2026 | Joseph M Palumbo | Buy | 4,843 | $2.16 |
| Aug 28, 2026 | Amy Suzon Chappell | Buy | 727 | $2.16 |
| Aug 28, 2026 | Amy Suzon Chappell | Buy | 727 | $2.16 |
| Aug 28, 2026 | Amy Suzon Chappell | Buy | 727 | $2.16 |
| Aug 28, 2026 | Amy Suzon Chappell | Buy | 727 | $2.16 |
| Aug 27, 2026 | Cuong V Do | Buy | 15,210 | $2.08 |
| Aug 27, 2026 | Cuong V Do | Buy | 15,210 | $2.08 |
| Aug 27, 2026 | Cuong V Do | Buy | 15,210 | $2.08 |
BIVIW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Jun 30, 2026 | — | $-22.07M | -3.05 | $-19.02M |
| Jun 30, 2025 | — | $-17.54M | -12.12 | $-19.03M |
| Jun 30, 2024 | — | $-32.12M | -73.05 | $-27.95M |
| Jun 30, 2023 | — | $-50.26M | -15.47 | $-40.25M |
| Jun 30, 2022 | — | $-26.08M | -1.06 | $-18.99M |
Latest balance sheet: total assets $14.25M, total liabilities $3.98M, cash $8.98M (as of Jun 30, 2026).
BIVIW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on BIVIW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.